Wall Street analyst estimates for Solid Biosciences Inc. (SLDB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $-0.37 | ||
| 2026-08-06 | $-0.38 | $-0.46 | +17.8% |
| 2026-05-12 | $-0.52 | $-0.40 | -30.0% |
| 2026-03-19 | $-0.50 | $-0.51 | +2.0% |
| 2025-11-03 | $-0.48 | $-0.42 | -14.3% |
| 2025-08-12 | $-0.42 | $-0.51 | +17.6% |
| 2025-05-15 | $-0.59 | $-0.53 | -11.3% |
| 2025-03-06 | $-0.89 | $-0.79 | -12.7% |
Valuation Ratios
| Price / Book | 3.35 |
| EV / EBITDA | -4.09 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $13.6M | $8.1M | 0 | 0 | 0 |
| Cost of Revenue | $56000 | 0 | $1.6M | $2.8M | $3.9M | 0 | 0 | $2.6M | $2.5M | $1.6M |
| Gross Profit | -$56000 | -$448000 | -$1.6M | -$2.8M | -$3.9M | $13.6M | $8.1M | -$2.6M | -$2.5M | -$1.6M |
| Research & Development | $20.1M | $39.9M | $58.0M | $94.7M | $64.9M | $58.7M | $78.4M | $76.6M | $96.4M | $140.3M |
| Selling, General & Admin | $5.5M | $15.0M | $17.7M | $24.6M | $21.6M | $27.1M | $28.9M | $27.8M | $33.3M | $38.9M |
| Operating Expenses | $25.6M | $54.9M | $75.7M | $119.3M | $82.5M | $85.9M | $114.5M | $101.7M | $127.3M | $177.6M |
| Operating Income | -$25.6M | -$54.9M | -$75.7M | -$119.3M | -$86.5M | -$72.3M | -$106.5M | -$104.3M | -$129.7M | -$179.2M |
| EBITDA | -$25.5M | -$54.4M | -$75.7M | -$116.5M | -$84.4M | -$69.2M | -$96.9M | -$93.4M | -$121.9M | -$172.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $340000 | 0 |
| Pre-tax Income | -$23.8M | -$53.2M | -$74.8M | -$117.2M | -$88.3M | -$72.2M | -$86.0M | -$96.0M | -$124.7M | -$174.3M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$21.5M | -$52.1M | -$74.8M | -$117.2M | -$88.3M | -$72.2M | -$86.0M | -$96.0M | -$124.7M | -$174.3M |
| EPS | $-16.80 | $-24.26 | $-33.73 | $-43.05 | $-25.50 | $-10.14 | $-10.10 | $-4.83 | $-3.06 | $-1.99 |
| EPS (Diluted) | $-16.80 | $-24.26 | $-33.73 | $-43.05 | $-25.50 | $-10.14 | $-10.10 | $-4.83 | $-3.06 | $-1.99 |
| Shares Outstanding (Diluted) | $1.3M | $2.1M | $2.2M | $2.7M | $3.5M | $7.1M | $8.5M | $19.9M | $40.8M | $87.5M |
Price
| Price | $8.72 |
| Market Cap | $858M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANNX · AURA · AUTL · BNTC · DSGN · LBRX · NMRA
Explore sector: Healthcare · Biotechnology
More sections of SLDB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks